Organ transplants are one of the
greatest advances in modern day medicine. Organ transplantation is a
medical procedure in which an organ is removed from one body and
transferred to another body to replace the missing or damaged organ.
One of the most important aspect of the organ transplantation is the
consent of the patient or the family of the patient. Organ harvesting
without proper consent is illegal and a massive crime. Organ
transplantation is mostly carried out with the brain dead patient
who’s other organs are healthy and can be used to save another
person’s life. The process of organ transplantation needs to be
done right after the death of the patient or within a couple of hours.
Kidneys are the most widely transplanted organ which is followed by
liver. Unfortunately, the need for organ donors is much higher than
the number of people who donate organs. According to the National
Kidney Foundation, more than 3,000 new patients are added to the
kidney waiting list each month worldwide. According to United Network
for Organ Sharing, 21 people die everyday in the United States
waiting for an organ, and more than 120,000 men, women and children
await lifesaving organ transplants.
CareDx, Inc.
One company dedicated to improving the
lives of organ transplant patients through noninvasive diagnostics is
CareDx, Inc. By combining the latest advances in genomics and
bioinformatics technology, with a commitment to generating high
quality clinical evidence through trials and registries, CareDx
strives to stay at the forefront of organ transplant surveillance
solutions. Based in Brisbane, Calif., CareDx stock (Nasdaq: CDNA)
leads the medical services sector with a major upswing over the past
year for investors.
Shares of CDNA are up 402
percent over the last 52 weeks (Nov. 20, 2017 to Nov. 16, 2018). This
year alone, the stock is up 308 percent, closing Friday at $29.95 per
share, up 0.81 percent for the day. CDNA has a 52-week low of $4.92
and high of $30.15.
The only dividend stock I see in the
medical services sector comes from Global Cord Blood Corp. (NYSE:
CO).
Global Cord Blood Corp.
Global Cord Blood Corp. is the first
and largest umbilical cord blood banking operator in China in terms
of geographical coverage and the only cord blood banking operator
with multiple licenses. Under current PRC government regulations,
only one licensed cord blood banking operator is permitted to operate
in each licensed region and no new licenses will be granted before
2020 in addition to the seven licenses authorized as of today. Global
Cord Blood Corp. provides cord blood collection, laboratory testing,
hematopoietic stem cell processing, and stem cell storage services.
Shares of CO are down 40
percent over the last 52 weeks (Nov. 20, 2017 to Nov. 16, 2018). This
year alone, the stock is down 34 percent, closing Friday at $6.53 per
share, down 2 percent for the day. CO has a 52-week low of $6.01 and
high of $12.25. The company issued a $0.08 dividend on July 31, 2018.
Disclaimer: This post is provided for information purposes only and should not be used as the basis for any investment decision. I am neither licensed nor qualified to provide investment advice. Keith Stein has no position in any stocks mentioned in this post. DCNewsroom has no position in any of the stocks mentioned in this post.
1 comment:
I am in favor of immediate donor/organ/transplants. However, I believe there is a big grey area in banking cord blood or any other kind of "banking" for later use. Too many possibilities for misuse or mix-ups.
Post a Comment